IKJ Capital
VC Fund
São Paulo, Brazil
IKJ Capital is a venture capital firm based in São Paulo and Palo Alto. We invest in early stage healthcare startups.
- Total investments:
- 38
- Last investment:
- Lead investor:
- 0%
- Fund size:
- $15M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries IKJ Capital invests in
Stages IKJ Capital invests in
Countries IKJ Capital invests in
Round sizes
Round size
- Seed
- $198k–$12M
- Pre-Seed
- $500k–$5M
- Series A
- $1.1M–$55M
Investment Focus
Industry
- Health Care 22 (58%)
- Medical 10 (26%)
- Artificial Intelligence 6 (16%)
- Biotechnology 5 (13%)
- Health Diagnostics 5 (13%)
Stage
- Seed 14 (37%)
- Series A 8 (21%)
- Pre-Seed 6 (16%)
- Venture - Series Unknown 3 (8%)
- Series B 2 (5%)
Country
- Brazil 11 (29%)
- United States 11 (29%)
- Canada 3 (8%)
- United Kingdom 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Fiibo is the first health and wellness multplatform in Brazil, offering an innovative technological solution that connects all healthcare stakeholders in one place. The platform includes an app that allows employees to choose from a variety of available products and services, as well as a data management and contracting platform for companies andbrokers. This provides greater freedom and flexibility in selecting how to care for one's health. | Seed / Aug 22, 2026 | ||
| Portal is a cell engineering platform firm that enables next generation cell engineering and cell analytics in research and clinical settings. | $9M / Seed / Jun 18, 2026 | ||
| Perspectives Health is an AI tool designed to streamline administrative tasks for behavioral health clinics. | $500K / Pre-Seed / Jul 03, 2025 | ||
| Eli empowers women to understand their body and the transitions it goes through every day, and across life. We develop a device that uses saliva to capture hormone fluctuations at home, and an app that gives women the information they want to own their health decisions. | $12M / Series A / Jun 10, 2025 | ||
| Portal is a cell engineering platform firm that enables next generation cell engineering and cell analytics in research and clinical settings. | $11.7M / Seed / Dec 19, 2024 | ||
| Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high-throughput, high-accuracy aging biomarker, which has been leveraged inside AI-based cell simulations toidentify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes accessible by simple prescription. | $16.3M / Seed / Oct 15, 2024 | ||
| Mevo is a healthcare platform that makes people's life simpler by providing everything from a digital prescription with an online purchase option for medicines to be delivered to their homes. Mevo is headquartered in São Paulo, Brazil and was founded in 2017. | $20.1M / Series B / Sep 18, 2024 | ||
| Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers thatcancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics. | Venture - Series Unknown / Aug 19, 2024 | ||
| The world's most comprehensive and convenient platform to manage your health, for life. | $4M / Pre-Seed / Apr 10, 2024 | ||
| Portal is a cell engineering platform firm that enables next generation cell engineering and cell analytics in research and clinical settings. | $5M / Pre-Seed / Mar 19, 2024 | ||
| See all 38 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does IKJ Capital invest in?
IKJ Capital invests primarily in Health Care, Medical and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 38 investments tracked by Shizune back companies in Brazil. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is IKJ Capital's check size?
IKJ Capital typically joins rounds of $198k–$12M at Seed, $500k–$5M at Pre-Seed and $1.1M–$55M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds IKJ Capital participates in.
When did IKJ Capital last invest?
The most recent investment recorded for IKJ Capital closed in Aug 2026. Shizune tracks 38 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
